GlassScriptPhysician profile
David M Deshan
NPI 1891706040
$1,504.13
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $198 · 2021: $430 · 2022: $618 · 2023: $56.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $56.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $56.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $462.41 | 2020-2022 | |
| Amgen INC. | $196.89 | 2019-2022 | |
| Astellas Pharma US INC | $170.16 | 2019-2023 | Veozah |
| Axonics, INC. | $92.84 | 2022-2023 | Axonics |
| Hologic Sales and Service, LLC | $73.25 | 2021 | |
| Allergan, INC. | $61.33 | 2019-2020 | |
| Daiichi Sankyo INC. | $57.79 | 2022 | |
| Arbor Pharmaceuticals, INC. | $52.57 | 2019 | |
| Coopersurgical, INC. | $45.91 | 2020 | |
| Lupin INC. | $42.83 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.92 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.98 | 2020-2022 | |
| Therapeuticsmd, INC. | $31.57 | 2022 | |
| Exeltis, USA INC. | $31.32 | 2020-2022 | |
| Ortho-Clinical Diagnostics, INC. | $21.49 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $17.54 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.78 | 2021 | |
| Organon LLC | $12.98 | 2022 | |
| Lilly USA, LLC | $12.52 | 2021 | |
| Avion Pharmaceuticals | $12.24 | 2021 | |
| Mission Pharmacal Company | $11.94 | 2020 | |
| Vertical Pharmaceuticals, LLC | $10.87 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Deshan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.